Abstract
It is unclear whether the combination of one or several mutations alters the clinical and epidemiological symptoms, infectivity, pathogenicity, or vaccine efficacy of the virus. The transmission of new mutants by asymptomatic carriers is also unidentified. Antiviral drugs or vaccines have not yet been induced. Mutation pressure; however, other mutations are expected after global vaccination and after introducing verified treatments. Therefore, it is wise to be willing to bring new options to life quickly. Low-toxicity but highly genetic mutants can also be expected, which might be part of herd immunity. Clinical and rapid laboratory tests need to be developed to monitor vaccinated individuals for secondary infections caused by new variants. Significantly, personal hygiene, spatial distancing, restrictive countermeasures, facial disguises, and travel bans remain applicable fighting against the virus.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
